On the stock market since 2021, it operates in the world of health and science. It has 1,926 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $721.3M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $2.8B in the vault; even if every debt were paid off, $721.3M would remain.
It pays out $0.02 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.47. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 9% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, SHEZF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SHEZF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.